Compare ILAG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILAG | JAGX |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.0M |
| IPO Year | 2020 | 2014 |
| Metric | ILAG | JAGX |
|---|---|---|
| Price | $2.27 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 4.3K | ★ 392.2K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,689,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.75 |
| 52 Week Low | $0.27 | $0.31 |
| 52 Week High | $7.19 | $15.48 |
| Indicator | ILAG | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 40.45 |
| Support Level | $2.06 | N/A |
| Resistance Level | $2.65 | $0.69 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 39.75 | 39.50 |
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.